Alzamend Neuro Files Proxy Statement Amendment
Ticker: ALZN · Form: DEFA14A · Filed: Mar 19, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | DEFA14A |
| Filed Date | Mar 19, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, amendment, sec-filing
TL;DR
Alzamend Neuro filed an amended proxy statement on 3/19/25. Definitive additional materials.
AI Summary
Alzamend Neuro, Inc. filed an amended proxy statement (DEFA14A) on March 19, 2025. This filing is an amendment to a previous filing and is considered definitive additional material. The company is incorporated in Delaware and its fiscal year ends on April 30. The filing fee was not required.
Why It Matters
This filing provides updated information to shareholders regarding company matters, which is crucial for informed voting decisions on corporate governance and strategic initiatives.
Risk Assessment
Risk Level: low — This is a routine proxy statement filing, not indicating any immediate financial or operational risks.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- 0001214659-25-004558.txt (document) — Filing document name
- 20250319 (date) — Filing date
- DEFA14A (document) — Form type
FAQ
What is the purpose of this DEFA14A filing?
This DEFA14A filing is an amendment (Amendment No. 2) to the proxy statement, filed as definitive additional materials.
Who is the registrant for this filing?
The registrant is Alzamend Neuro, Inc.
When was this filing made?
The filing was made on March 19, 2025.
What is the fiscal year end for Alzamend Neuro, Inc.?
The fiscal year end for Alzamend Neuro, Inc. is April 30.
Was there a filing fee required for this document?
No fee was required for this filing, as indicated by the 'No fee required' checkbox being selected.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on March 19, 2025 regarding Alzamend Neuro, Inc. (ALZN).